Bioceres Crop Solutions (BIOX) Q1 2025 earnings summary

Executive summary

• Fiscal Q1 2025 revenue was $93.3 million, down 20% year-over-year, mainly due to drought and a slow crop season in Argentina, while North America and Brazil showed growth and partially offset declines.

• Net loss was $5.3 million, compared to $2.7 million in 1Q24; Adjusted EBITDA was $8.5 million, down 48% year-over-year.

• Portfolio diversification and international growth, especially in North America and Brazil, partially offset weather-related challenges.

• Regulatory milestones achieved, including EPA Green Chemistry Award for RinoTec technology and HB4 soybean cultivation approvals in Uruguay and Bolivia, completing clearance in all major soybean-producing countries in the Americas.

• Strategic shift in HB4 commercialization from identity-preserved to conventional sales, aiming for higher margins and lower capital intensity.

Financial highlights

• Revenues declined 20% year-over-year to $93.3 million, primarily due to lower product use in Argentina and reduced HB4 downstream sales.

• Gross profit decreased 17% to $37.5 million, but gross margin improved to 40.2% from 38.6% year-over-year due to a focus on higher-margin products.

• Net loss widened to $5.3 million from $2.7 million in the prior year quarter.

• Adjusted EBITDA dropped to $8.5 million from $16.3 million year-over-year.

• Debt net of cash and short-term investments rose to $212.0 million from $183.4 million a year ago; total debt at $250.2 million as of September 30, 2024.

Outlook and guidance

• Recent rainfall in Argentina has improved farmer sentiment and is expected to boost Q2 sales, especially in crop protection.

• North America and Brazil are gaining traction, with a focus on cash generation.

• Capital allocation will focus on lower-risk, quicker-payback products and technologies, with disciplined working capital management.

• Optimism for the remainder of the fiscal year due to normalized weather and international momentum.

• Strategy revision for HB4/seeds aims to accelerate transition from IP to conventional sales and explore alternative monetization channels.